<div id="readability-page-1"><p>Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CTO Paul Herzich sold 2,701 shares of the stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $5.11, for a total transaction of $13,802.11. Following the completion of the sale, the chief technology officer directly owned 26,622 shares in the company, valued at approximately $136,038.42. The trade was a 9.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.</p><div><p><span></span><span>Get <strong>Solid Biosciences</strong> alerts:</span></p></div><h2>Solid Biosciences Price Performance</h2><ul><li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li></ul><p>NASDAQ:SLDB traded up $0.73 during trading hours on Thursday, hitting $5.92. The stock had a trading volume of 1,597,041 shares, compared to its average volume of 1,655,025. The firm has a market capitalization of $461.23 million, a price-to-earnings ratio of -2.38 and a beta of 2.97. Solid Biosciences Inc. has a one year low of $2.41 and a one year high of $7.37. The company has a 50 day simple moving average of $5.34 and a two-hundred day simple moving average of $5.26. </p><p>Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06).  Equities research analysts anticipate that  Solid Biosciences Inc. will post -2.84 earnings per share for the current year. </p><h2>Analysts Set New Price Targets</h2><ul><li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li></ul><p>Several analysts have recently weighed in on SLDB shares. JPMorgan Chase &amp; Co. lowered their price objective on shares of Solid Biosciences from $13.00 to $11.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, November 5th. Chardan Capital  reissued a &#34;buy&#34; rating and set a $15.00 price objective on shares of Solid Biosciences in a research note on Tuesday, November 4th. Needham &amp; Company LLC assumed coverage on Solid Biosciences in a research note on Thursday. They issued a &#34;buy&#34; rating and a $16.00 target price on the stock. Wall Street Zen cut shares of Solid Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Sunday, October 19th. Finally, Barclays  set a $9.00 target price on Solid Biosciences and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, November 4th. One research analyst  has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $14.82.</p><p><b>View Our Latest Report on SLDB</b></p><h2>Institutional Trading of Solid Biosciences</h2><ul><li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li></ul><p>A number of institutional investors and hedge funds have recently modified their holdings of SLDB. Bain Capital Life Sciences Investors LLC increased its holdings in  Solid Biosciences by 96.1% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock worth $29,273,000 after buying an additional 3,877,087 shares in the last quarter.  Siren L.L.C. increased its holdings in  Solid Biosciences by 97.8% during the first quarter. Siren L.L.C. now owns 7,415,905 shares of the company's stock valued at $27,439,000 after buying an additional 3,666,864 shares during the last quarter.  Adage Capital Partners GP L.L.C. increased its stake in shares of  Solid Biosciences by 285.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company's stock worth $24,899,000 after purchasing an additional 4,981,400 shares in the last quarter.  Vestal Point Capital LP increased its position in  Solid Biosciences by 97.7% in the third quarter. Vestal Point Capital LP now owns 2,975,000 shares of the company's stock worth $18,356,000 after buying an additional 1,470,000 shares in the last quarter.  Finally, Redmile Group LLC increased its holdings in  Solid Biosciences by 228.2% in the 1st quarter. Redmile Group LLC now owns 2,019,171 shares of the company's stock worth $7,471,000 after acquiring an additional 1,403,925 shares in the last quarter. Institutional investors own  81.46% of the company's stock. </p><h2>Solid Biosciences Company Profile</h2> (Get Free Report)<p>Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Solid Biosciences</li><li>How to Short a Stock in 5 Easy Steps </li><li>Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF</li><li>3 REITs to Buy and Hold for the Long Term</li><li>Strong Quarter, Weak Reaction: Why GitLab Shares Dropped</li><li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li><li>3 Signs Tesla Is Starting December on the Front Foot</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Solid Biosciences Right Now?</h2><p>Before you consider Solid Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.</p><p>While Solid Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SLDB

<p>Solid Biosciences CTO Paul Herzich sold 2,701 shares at $5.11 each, totaling $13,802.11, reducing his position by 9.21%. Post-sale, he owns 26,622 shares valued at $136,038.42. The sale was disclosed in an SEC filing. SLDB stock rose to $5.92, with a market cap of $461.23 million. Analysts have mixed ratings, with a moderate buy consensus and a target price of $14.82. Institutional investors hold 81.46% of SLDB shares, with significant recent increases in holdings.</p>

Insider Selling: Solid Biosciences (NASDAQ:SLDB) CTO Sells 2,701 Shares of Stock